Email this article 
Hide
Show all
Review Article
Update on ocular toxicity of ethambutol
Submitted: 09 March 2016 | Published: 30 August 2016
About the author(s)
Priscilla Makunyane, Department of Ophthalmology, University of Pretoria, South AfricaSolani Mathebula, Department of Optometry, University of Limpopo, South Africa
Abstract
The purpose of this review is to update clinicians on available literature on the ocular toxicity of ethambutol and the type of eye care to be provided to patients treated with these medications. Ethambutol is a commonly used first-line anti-tuberculosis drug. Since its first use in the 1960s, ocular toxicity is described as related to dose and duration, and it is reversible on therapy discontinuation. However, the reversibility of the toxic optic neuropathy remains controversial. The mechanism of ocular toxicity owing to ethambutol is still under investigation. Other than discontinuing the drug, no specific treatment is available for the optic neuropathy caused by ethambutol. Doctors prescribing ethambutol should be aware of the ocular toxicity, and the drug should be used with proper patient education and ophthalmic monitoring.
Keywords
Metrics
Total abstract views: 9208Total article views: 27790
Crossref Citations
1. Exploration of the Plausible Mechanism of Ethambutol Induced Ocular Toxicity by Using Proteomics Informed Physiologically Based Pharmacokinetic (PBPK) Modeling
Ankit Balhara, Mayur K. Ladumor, Rakesh P. Nankar, Samiulla Dodheri Syed, Sanjeev Giri, Bhagwat Prasad, Saranjit Singh
Pharmaceutical Research vol: 39 issue: 4 first page: 677 year: 2022
doi: 10.1007/s11095-022-03227-9
2. Visual evoked potential as an early assessment tool in ethambutol-induced toxic optic neuropathy during treatment of tuberculosis
Anita Misra, Santosh Kumar Sethi, Partha Singh
Indian Journal of Clinical and Experimental Ophthalmology vol: 10 issue: 2 first page: 373 year: 2024
doi: 10.18231/j.ijceo.2024.066
3. Molecular insights of hyaluronic acid – ethambutol and hyaluronic acid – isoniazid drug conjugates act as promising novel drugs for the treatment of tuberculosis
R. Thirumalaisamy, V. Aroulmoji, Muhammad Nasir Iqbal, Shreyas Saride, M. Bhuvaneswari, M. Deepa, C. Sivasankar, Riaz Khan
Journal of Biomolecular Structure and Dynamics vol: 41 issue: 8 first page: 3562 year: 2023
doi: 10.1080/07391102.2022.2051748
4. Mechanism of Apoptosis Retinal Ganglion Cells Rattus norvegicus Caused by Ethambutol
Lukisiari Agustini, Nurwasis Nurwasis, Aryati Aryati, Gatut Suhendro, Winarto Winarto, I Ketut Sudiana, Widjiati Widjiati, Bambang Purwanto
Research Journal of Pharmacy and Technology first page: 1795 year: 2022
doi: 10.52711/0974-360X.2022.00301
5. Ocular side effects of anti-tubercular drugs in patients receiving Anti-Tb treatment at tertiary care center
Kruti Panchal, Trupti M Solu
IP International Journal of Ocular Oncology and Oculoplasty vol: 6 issue: 3 first page: 187 year: 2020
doi: 10.18231/j.ijooo.2020.042